Global Custom Market Research Reports Provider Company

phone

Crigler-Najjar Syndrome - Pipeline Review, H1 2018

  • Published Date: 27 Feb 2018
  • Number of Pages: 34
  • Category: Pharmaceuticals
  • Country: Global

Crigler-Najjar Syndrome - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides an overview of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape.

Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Symptoms include yellow skin (jaundice) and yellow in the whites of the eyes (icterus). It occurs when the enzyme that normally converts bilirubin into a form that can easily be removed from the body does not work correctly. Treatment includes phototherapy, liver transplantation and blood transfusions.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Crigler-Najjar Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crigler-Najjar Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crigler-Najjar Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.Crigler-Najjar Syndrome - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides an overview of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape.

Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Symptoms include yellow skin (jaundice) and yellow in the whites of the eyes (icterus). It occurs when the enzyme that normally converts bilirubin into a form that can easily be removed from the body does not work correctly. Treatment includes phototherapy, liver transplantation and blood transfusions.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Crigler-Najjar Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crigler-Najjar Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crigler-Najjar Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.Crigler-Najjar Syndrome - Pipeline Review, H1 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides an overview of the Crigler-Najjar Syndrome (Genetic Disorders) pipeline landscape.

Crigler-Najjar syndrome is a severe condition characterized by high levels of a toxic substance called bilirubin in the blood (hyperbilirubinemia). Symptoms include yellow skin (jaundice) and yellow in the whites of the eyes (icterus). It occurs when the enzyme that normally converts bilirubin into a form that can easily be removed from the body does not work correctly. Treatment includes phototherapy, liver transplantation and blood transfusions.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Crigler-Najjar Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Crigler-Najjar Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Crigler-Najjar Syndrome (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Crigler-Najjar Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Crigler-Najjar Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Crigler-Najjar Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Crigler-Najjar Syndrome (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Crigler-Najjar Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
  

Publisher Name : Global Markets Direct


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Crigler-Najjar Syndrome - Overview
Crigler-Najjar Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Crigler-Najjar Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Crigler-Najjar Syndrome - Companies Involved in Therapeutics Development
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Crigler-Najjar Syndrome - Drug Profiles
AT-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucuronosyltransferase for Crigler-Najjar Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNT-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Crigler-Najjar Syndrome - Dormant Projects
Crigler-Najjar Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 12, 2018: Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
Nov 13, 2017: Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome
May 03, 2017: Audentes Therapeutics Announces Presentation of Data on at the American Society of Gene and Cell Therapy Annual Meeting
Mar 01, 2017: Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
Feb 01, 2017: Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Feb 12, 2013: International Stem Cell Demonstrates Positive Animal Efficacy Results In Metabolic Liver Disease Program
Jan 07, 2013: International Stem Cell Announces Positive Animal Efficacy Results In Liver Disease Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerTable of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Crigler-Najjar Syndrome - Overview
Crigler-Najjar Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Crigler-Najjar Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Crigler-Najjar Syndrome - Companies Involved in Therapeutics Development
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Crigler-Najjar Syndrome - Drug Profiles
AT-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucuronosyltransferase for Crigler-Najjar Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNT-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Crigler-Najjar Syndrome - Dormant Projects
Crigler-Najjar Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 12, 2018: Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
Nov 13, 2017: Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome
May 03, 2017: Audentes Therapeutics Announces Presentation of Data on at the American Society of Gene and Cell Therapy Annual Meeting
Mar 01, 2017: Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
Feb 01, 2017: Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Feb 12, 2013: International Stem Cell Demonstrates Positive Animal Efficacy Results In Metabolic Liver Disease Program
Jan 07, 2013: International Stem Cell Announces Positive Animal Efficacy Results In Liver Disease Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
DisclaimerTable of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Crigler-Najjar Syndrome - Overview
Crigler-Najjar Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Crigler-Najjar Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Crigler-Najjar Syndrome - Companies Involved in Therapeutics Development
Audentes Therapeutics Inc
Genethon SA
International Stem Cell Corp
Promethera Biosciences SA
Crigler-Najjar Syndrome - Drug Profiles
AT-342 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Glucuronosyltransferase for Crigler-Najjar Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GNT-0003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HepaStem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Crigler-Najjar Syndrome - Dormant Projects
Crigler-Najjar Syndrome - Product Development Milestones
Featured News & Press Releases
Feb 12, 2018: Audentes Therapeutics Announces Dosing of First Patient in VALENS, a Phase 1/2 Clinical Trial of AT342 for the treatment of Crigler-Najjar Syndrome
Nov 13, 2017: Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome
May 03, 2017: Audentes Therapeutics Announces Presentation of Data on at the American Society of Gene and Cell Therapy Annual Meeting
Mar 01, 2017: Audentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
Feb 01, 2017: Audentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
Feb 12, 2013: International Stem Cell Demonstrates Positive Animal Efficacy Results In Metabolic Liver Disease Program
Jan 07, 2013: International Stem Cell Announces Positive Animal Efficacy Results In Liver Disease Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
  



List Of Tables

List of Tables
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Crigler-Najjar Syndrome - Pipeline by Audentes Therapeutics Inc, H1 2018
Crigler-Najjar Syndrome - Pipeline by Genethon SA, H1 2018
Crigler-Najjar Syndrome - Pipeline by International Stem Cell Corp, H1 2018
Crigler-Najjar Syndrome - Pipeline by Promethera Biosciences SA, H1 2018
Crigler-Najjar Syndrome - Dormant Projects, H1 2018List of Tables
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Crigler-Najjar Syndrome - Pipeline by Audentes Therapeutics Inc, H1 2018
Crigler-Najjar Syndrome - Pipeline by Genethon SA, H1 2018
Crigler-Najjar Syndrome - Pipeline by International Stem Cell Corp, H1 2018
Crigler-Najjar Syndrome - Pipeline by Promethera Biosciences SA, H1 2018
Crigler-Najjar Syndrome - Dormant Projects, H1 2018List of Tables
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Crigler-Najjar Syndrome - Pipeline by Audentes Therapeutics Inc, H1 2018
Crigler-Najjar Syndrome - Pipeline by Genethon SA, H1 2018
Crigler-Najjar Syndrome - Pipeline by International Stem Cell Corp, H1 2018
Crigler-Najjar Syndrome - Pipeline by Promethera Biosciences SA, H1 2018
Crigler-Najjar Syndrome - Dormant Projects, H1 2018
  



List Of Figures

List of Figures
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018List of Figures
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018List of Figures
Number of Products under Development for Crigler-Najjar Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  



Crigler-Najjar Syndrome - Pipeline Review, H1 2018 Summary Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2018, provides an overview of the

View Report

Crigler-Najjar Syndrome - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H2 2017, provides an overview of the Crigler-Najjar Syndrome

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports